CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript
CareDx, Inc. (NASDAQ:CDNA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and CEO Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Alex Johnson - President, Patient and Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Kayla Hostetler - Jefferies Prashant Kota - Goldman Sachs Andrew Cooper - Raymond James Nathan Kariko - Stephens Vivian Bais - BTIG Yi Chen - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good day, everyone.
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
CareDx (CDNA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.18 per share a year ago.
